Treatment of community-acquired pneumonia with moxifloxacin: A meta-analysis of randomized controlled trials

Journal of Chemotherapy

Volumn 24, Issue 5, 2012, Pages 257-267

  Yuan, Xin ^a,b   Liang, Bei Bei ^a   Wang, Rui ^a   Liu, You Ning ^a   Sun, Chun Guang ^a   Cai, Yun ^a   Zhao, Tie Mei ^a   Bai, Nan ^a   Xu Hong, Yu ^a   Cui, Jun Chang ^a   Chen, Liang An ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

Author keywords

Community acquired pneumonia; Meta analysis; Moxifloxacin

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; CEFOPERAZONE; CEFTRIAXONE; CEFUROXIME; CLARITHROMYCIN; ERYTHROMYCIN; LEVOFLOXACIN; MACROLIDE; MOXIFLOXACIN; ROXITHROMYCIN;

ANTIBIOTIC THERAPY; ARTICLE; CHLAMYDIA; CLINICAL EFFECTIVENESS; COCHRANE LIBRARY; COMMUNITY ACQUIRED PNEUMONIA; DIARRHEA; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; EMBASE; GASTROINTESTINAL SYMPTOM; HAEMOPHILUS INFLUENZAE; HUMAN; KLEBSIELLA PNEUMONIAE; MEDLINE; META ANALYSIS; MONOTHERAPY; MORAXELLA CATARRHALIS; MORTALITY; MYCOPLASMA; NAUSEA; RANDOMIZED CONTROLLED TRIAL (TOPIC); STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VOMITING;

ANTI-BACTERIAL AGENTS; AZA COMPOUNDS; COMMUNITY-ACQUIRED INFECTIONS; HUMANS; PNEUMONIA, BACTERIAL; QUINOLINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84866641556     PISSN: 1120009X     EISSN: 19739478     Source Type: Journal    
DOI: 10.1179/1973947812Y.0000000028     Document Type: Article

References (38)

1. Brueggemann AB, Kugler KC, Doern GV. In vitro activity of BAY 12-8039, a novel 8-methoxyquinolone, compared to activities of six fluoroquinolones against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis. Antimicrob Agents Chemother. 1997;41:1594-7.
2. Jones ME, Staples AM, Critchley I, Thornsberry C, Heinze P, Enjler HD, et al. Benchmarking the in vitro activities of moxifloxacin and comparator agents against recent respiratory isolates from 377 medical centers throughout the United States. Antimicrob Agents Chemother. 2000;44:2645-52.
3. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds JM, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17:1-12.
4. Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? Lancet. 1998;352:609-13.
5. Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629-34.
6. Petitpretz P, Arvis P, Marel M, Moita J, Urueta J. CAP5 Moxifloxacin Study Group. Oral moxifloxacin vs. high-dosage amoxicillin in the treatment of mild-to-moderate, community-acquired, suspected pneumococcal pneumonia in adults. Chest. 2001;119:185-95.
7. Finch R, Schurmann D, Collins O, Kubin R, McGivern J, Bobbaers H, et al. Randomized Controlled Trial of Sequential Intravenous (i.v.) and Oral Moxifloxacin Compared with Sequential i.v. and Oral Co-Amoxiclav with or without Clarithromycin in Patients with Community-Acquired Pneumonia Requiring Initial Parenteral Treatment. Antimicrob Agents Chemother. 2002;46:1746-54.
8. Jardim JR, Rico G, de la Roza C, Obispo E, Urueta J, Wolff M, et al. A comparison of moxifloxacin and amoxicillin in the treatment of community-acquired pneumonia in Latin America: Results of a multicenter clinical trial. Archivos de Bronconeumologia. 2003;39(9):387-93.
9. Torres A, Muir JF, Corris P, Kubin R, Duprat-Lomon I, Sagnier PP, et al. Effectiveness of oral moxifloxacin in standard first-line therapy in community-acquired pneumonia. Eur Respir J. 2003;21:135-43.
10. Katz E, Larsen LS, Fogarty CM, Hamed K, Song J, Choudhri S. Safety and efficacy of sequential i.v. to p.o. moxifloxacin versus conventional combination therapies for the treatment of community-acquired pneumonia in patients requiring initial i.v. therapy. J Emerg Med. 2004;27:395-405.
11. Welte T, Petermann W, Schurmann D, Bauer TT, Reimnitz P, Study Group Moxirapid. Treatment with Sequential Intravenous or Oral Moxifloxacin Was Associated with Faster Clinical Improvement than Was Standard Therapy for Hospitalized Patients with Community-Acquired Pneumonia Who Received Initial Parenteral Therapy. Clin Infect Dis. 2005;41:1697-705.
12. Portier H, Brambilla C, Garre M, Paganin F, Poubeau P, Zuck P. Moxifloxacin monotherapy compared to amoxicillin-clavu-lanate plus roxithromycin for nonsevere community-acquired pneumonia in adults with risk factors. Eur J Clin Microbiol Infect Dis. 2005;24:367-76.
13. Xu S, Xiong S, Xu Y, Liu J, Liu H, Zhao J, et al. Efficacy and safety of intravenous moxifloxacin versus cefoperazone with azithromycin in the treatment of community acquired pneu-monia. J Huazhong Univ Sci Technolog Med Sci. 2006;26:421-4.
14. Torres A, Garau J, Arvis P, Carlet J, Choudhri S, Kureishi A, et al. Moxifloxacin monotherapy is effective in hospitalized patients with community-acquired pneumonia: the MOTIV study a randomized clinical trial. Clin Infect Dis. 2008;46:1499-509.
15. File TM Jr, Larsen LS, Fogarty CM, Schechter RB, Peloquin S, Choudhri S., et al. Safety and efficacy of sequential (IV to PO) moxifloxacin for the treatment of community-acquired pneu-monia in hospitalized patients. Today's Therapeutic Trends. 2001;19:251-70.
16. Hiroyuki K, Nobuki A, Yoshihito N, Akira W, Shin K, Shigeki O, et al. Phase III double-blind comparative study of BAY 12-8039 (moxifloxacin) versus levofloxacin in patients with community-acquired pneumonia. Jpn J Chemother. 2005;53(s-3):27-46.
17. Anzueto A, Niederman MS, Pearle J, Restrepo MI, Heyder A, Choudhri S., et al. Community-acquired pneumonia recovery in the elderly (CAPRIE): Efficacy and safety of moxifloxacin therapy versus that of levofloxacin therapy. Clin Infect Dis. 2006;42:73-81.
18. Ferrara AM. A brief review of moxifloxacin in the treatment of elderly patients with community-acquired pneumonia (CAP). Clin Intery Aging. 2007;2:179-87.
19. Nawar EW, Niska RW, Xu J. National Hospital Ambulatory Medical Care Survey: 2005 emergency department summary. Adv Data. 2007;386:1-32.
20. Healthcare Cost and Utilization Project Nationwide Inpatient Sample 2006. [cited 2008 Aug 12]. Available from: http://hcupnet.ahrq.gov.
21. Trotter CL, Stuart JM, George R, Miller E. Increasing hospital admissions for pneumonia. Emerg Infect Dis. 2008;14:727-33.
22. Rello J, Catalan M, Diaz E, Bodi M, Alvarez B. Associations between empirical antimicrobial therapy at the hospital and mortality in patients with severe community-acquired pneumonia. Intensive Care Med. 2002;28:1030-5.
23. Whitney CG, Farley MM, Hadler J, Harrison LH, Lexau C, Reingold A, et al. Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States. N Engl J Med. 2000;343:1917-24.
24. Thornsberry C, Sahm DF, Kelly LJ, Critchley IA, Jones ME, Evangelista AT et al. Regional trends in antimicrobial resistance among clinical isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States: results from the TRUST Surveillance Program, 1999-2000. Clin Infect Dis. 2002;34(Suppl. 1):S4-16.
25. McCormick AW, Whitney CG, Farley MM, Lynfield R, Harrison LE, Bennett NM, et al. Geographic diversity and temporal trends of antimicrobial resistance in Streptococcus pneumoniae in the United States. Nat Med. 2003;9:424-30.
26. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007;44(Suppl 2):527-72.
27. Iannini PB. The safety profile of moxifloxacin and other fluoroquinolones in special patient populations. Curr Med Res Opin. 2007;23(9):2303.
28. Fogarty C, Grossman C, Williams J, Haverstock D, Church D. Efficacy and safety of moxifloxacin vs. clarithromycin for community-acquired pneumonia. Infect Med. 1999;16(11):748-63
29. Hoeffken G, Meyer HP, Winter J, Verhoef L, CAP1 Study Group. The efficacy and safety of two oral moxifloxacin regimens (200 mg or 400 mg once-daily x 10 days) compared to oral clarithromycin (500 mg twice-daily x 10 days) in the treatment of community-acquired pneumonia. Respir Med. 2001;95:553-64.
30. Lode H, Grossmanb C, Choudhric S, Haverstock D, McGivern J, Herman-Gnjidic Z, et al. Sequential IV/PO moxifloxacin treatment of patients with severe community-acquired pneu-monia. Respir Med. 2003;97:1134-42.
31. Hoeffken G, Talan D, Larsen LS, Peloquin S, Choudhri S., Haverstock D, et al. Efficacy and safety of sequential moxifloxacin for treatment of community-acquired pneumonia associated with atypical pathogens. Eur J Clin Microbiol Infect Dis. 2004;23:772-5.
32. An MM, Zou Z, Shen H, Gao PH, Cao YB, Jiang YY. Moxifloxacin monotherapy versus beta-lactam-based standard therapy for community-acquired pneumonia: a meta-analysis of randomised controlled trials. Int J Antimicrob Agents. 2010;36:58-65.
33. Vardarkas KZ, Siempos II, Grammatikos A, Athanassa Z, Korbila IP, Falagas ME. Respiratory fluoroquinolones for the treatment of community-acquired pneumonia: a meta-analysis of randomized controlled trials. CMAJ. 2008;179(12):1269-77.
34. Van Bambeke F, Tulkens PM. Safety profile of the respiratory fluoroquinolone moxifloxacin: comparison with other fluor-oquinolones and other antibacterial classes. Drug Safety. 2009;32:359-78.
35. Morganroth J, DiMarco JP, Anzueto A, Niederman MS, Choudhri S, CAPRIE Study Group. A Randomized Trial Comparing the Cardiac Rhythm Safety of Moxifloxacin vs. Levofloxacin in Elderly Patients Hospitalized With Community-Acquired Pneumonia. Chest. 2005;128:3398-406.
36. Stass H, Kubitza D. Basic pharmaocokinetics of moxifloxacin. Drugs. 1999;58(Suppl 2):225-6.
37. Stass H. Metabolism and excretion of moxifloxacin. Drugs. 1999;58:231-2.
38. Dalhoff A. Dissociated resistance among fluoroquinolones. Poster presented at First International Moxifloxacin Symposium; 1999; Berlin, Germany.